Summarized by Masters of Longevity from Longevity Technology.
A concise news piece previewing a long-term clinical follow-up on a single-dose gene therapy for diabetic retinopathy, focusing on durability and safety implications.
Key Takeaways
- In Phase II ALTITUDE long-term follow-up, 60% of dose level 3 participants achieved >2-step DRSS improvement without further treatment.
- Dose level 3 was 1.0×10^12 GC per eye administered via an in-office suprachoroidal injection.
- No vision-threatening events were reported among the dose level 3 participants through three years.
